Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

JD Oliner, JA Pietenpol, S Thiagalingam, J Gyuris… - Nature, 1993 - nature.com
JD Oliner, JA Pietenpol, S Thiagalingam, J Gyuris, KW Kinzler, B Vogelstein
Nature, 1993nature.com
THE tumour-suppressor gene p53 is inactivated in most human malignancies1 either by
missense mutations1 or by binding to oncogenic proteins2–4. In human soft tissue
sarcomas, inactivation apparently results from MDM2 gene amplification4. MDM2 is an
oncogene product5, 6 that may function by binding to p53 and inhibiting its ability to activate
transcription3. Here we show that, when expressed in Saccharomyces cerevisiae, human
MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that …
Abstract
THE tumour-suppressor gene p53 is inactivated in most human malignancies1 either by missense mutations1 or by binding to oncogenic proteins2–4. In human soft tissue sarcomas, inactivation apparently results from MDM2 gene amplification4. MDM2 is an oncogene product5,6 that may function by binding to p53 and inhibiting its ability to activate transcription3. Here we show that, when expressed in Saccharomyces cerevisiae, human MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that nearly coincides with the p53 acidic activation domain. The isolated p53 activation domain fused to another DNA-binding protein is also inactivated by MDM2, confirming that MDM2 can inhibit p53 function by concealing the activation domain of p53 from the cellular transcription machinery.
nature.com